10-QPeriod: Q2 FY2003

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2003

Filed August 14, 2003For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a net loss of $89.9 million for the three months ended June 30, 2003, compared to a net loss of $21.0 million for the same period in the prior year. This widened loss was primarily driven by a significant restructuring and other expense of $44.1 million related to operational restructuring, including a facility lease modification and workforce reduction. The company also saw a substantial decrease in revenue from its Discovery Tools and Services segment, largely due to the sale of certain assets to Invitrogen Corporation in March 2003, which did, however, result in a significant gain on sale of assets ($69.2 million) recognized in the first quarter. Pharmaceutical revenues saw a slight decrease, primarily due to the conclusion of certain research collaborations. Despite the increased net loss, Vertex continues to invest heavily in its Pharmaceuticals segment, with R&D expenses growing by 9% year-over-year for the quarter, driven by the advancement of its drug candidates in various stages of clinical development. The company ended the period with a strong cash and marketable securities balance of $633.4 million, providing liquidity for ongoing operations and future investments. Management expects to incur losses for the foreseeable future due to continued R&D investment, but anticipates commercializing multiple products and generating increased revenues in the coming years.

Key Highlights

  • 1Significant increase in net loss to $89.9 million for Q2 2003, compared to $21.0 million in Q2 2002, impacted by a substantial restructuring charge.
  • 2Restructuring and other expenses of $44.1 million for the quarter, primarily for lease restructuring and workforce reduction, are expected to yield annual operating cost savings.
  • 3Revenue from the Discovery Tools and Services segment significantly declined by 93% year-over-year for the quarter, following the divestiture of certain assets.
  • 4Pharmaceuticals segment revenues saw a decrease, with royalties down 15% and collaborative R&D revenue down 26% for the quarter, mainly due to the conclusion of research collaborations.
  • 5Research and Development expenses increased by 9% to $50.7 million for the quarter, reflecting continued investment in advancing drug candidates, including Phase I and II trials.
  • 6The company realized a $69.2 million gain on the sale of certain assets from its Discovery Tools and Services business in the first quarter of 2003.
  • 7Vertex maintained a robust liquidity position with $633.4 million in cash and marketable securities as of June 30, 2003, sufficient to fund operations.

Frequently Asked Questions

The primary reason for the increased net loss in the three months ended June 30, 2003, compared to the same period last year, is a substantial restructuring and other expense of $44.1 million. This expense is related to a plan to restructure operations, including workforce reductions and significant lease restructuring costs for facilities.

The sale of certain assets from the Discovery Tools and Services business to Invitrogen Corporation in March 2003 resulted in a gain on sale of assets of approximately $69.2 million, recognized in the first quarter of 2003. This sale also led to a significant decrease in revenue from this segment, as product sales and service revenues dropped substantially year-over-year.

Vertex Pharmaceuticals is heavily investing in its Pharmaceuticals segment, with R&D expenses increasing to $50.7 million for the quarter ended June 30, 2003. This investment is focused on advancing drug candidates through various clinical trial phases (Phase I, II, and preclinical) for conditions such as infectious diseases, inflammation, autoimmune diseases, cancer, and neurological disorders. Management expects R&D expenses to continue to be substantial as they pursue long-term objectives.

As of June 30, 2003, Vertex Pharmaceuticals had $633.4 million in cash and marketable securities. While the company expects to incur losses for the foreseeable future due to ongoing R&D investments, this substantial cash balance provides significant liquidity to fund operations, clinical development, and potential future strategic initiatives.